KLRS
Kalaris Therapeutics, Inc.
NASDAQ: KLRS · HEALTHCARE · BIOTECHNOLOGY
$5.52
+0.18% today
Updated 2026-04-30
Market cap
$138.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.85
Dividend yield
—
52W range
$2 – $12
Volume
0.1M
Kalaris Therapeutics, Inc. (KLRS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | $25.32M | $139.42M | $370.82M | $286.59M | $3.90M | $3.33M | $118.55M |
| Cash & equivalents | $24.96M | $61.08M | $122.66M | $201.66M | $3.06M | $3.17M | $118.29M |
| Current assets | $25.31M | $127.31M | $361.32M | $253.35M | $3.90M | $3.33M | $118.55M |
| Total liabilities | $3.74M | $17.80M | $17.76M | $61.33M | $34.17M | $48.35M | $5.24M |
| Current liabilities | $3.74M | $9.11M | $12.29M | $37.85M | $5.69M | $3.94M | $5.24M |
| Long-term debt | — | — | — | — | $3.25M | — | — |
| Shareholder equity | $21.58M | $121.62M | $353.06M | $225.27M | $-30.27M | $-45.02M | $113.31M |
| Retained earnings | $-31.48M | $-55.32M | $-125.10M | $-297.06M | $-32.70M | $-47.39M | $-714.96M |
| Accounts receivable | $302000.00 | $560000.00 | $450000.00 | $50000.00 | — | — | — |
| Inventory | — | — | — | — | — | — | — |
| Goodwill | — | — | — | — | — | — | — |